Diverse biomarkers, including PSA, BRCA mutations, PSMA, and AR-V7, guide treatment decisions in advanced prostate cancer management. Emerging biomarkers like ctDNA and PTEN loss offer predictive and ...

Precision-based care is enhancing urologic diagnostics, reducing unnecessary interventions, and improving treatment personalization, particularly in prostate cancer. Workforce shortages and an aging ...

Ibex Prostate Detect uses AI to analyze prostate biopsy images, generating heatmaps and alerts to assist pathologists in identifying missed tumors. The software achieved a 99.6% positive predictive ...

Smerina and Pearlman discuss recent research collaborations in the field of sexual medicine. In this video, from the 2025 Desai Sethi Urology Institute Urology on the Beach meeting, Dayna R. Smerina ...

"We need to promote further research and guidelines for safe use of these natural products, because I think we're missing out if we don't monitor them," says Channing J. Paller, MD. In this video, ...

"I want to add that the safety profile was impeccable for this. No one experienced a [device-related] adverse event," says Matthew J. Mutter, MD. In this video, Matthew J. Mutter, MD, highlights ...

"A lot of shared decision-making has to do with, what is important to the individual man?" says Dean S. Elterman, MD, MSc, FRCSC. In this interview, Dean S. Elterman, MD, MSc, FRCSC, gives an overview ...

"My second book is on pelvic pain or prostatitis. It is focused on a holistic approach and stretches and mindfulness exercises," says Vanita Gaglani, RPT. In this video, Vanita Gaglani, RPT, discusses ...

The Revi System showed sustained efficacy at 24 months, with 79% of patients responding to therapy and significant reductions in UUI episodes. Patient satisfaction was high, with 97% satisfied and 80% ...

Anktiva is the first drug to rescue T and NK cells, crucial for cancer cell eradication and memory generation. The "triangle offense" involves NK cells, CD8 killer T cells, and memory T cells, forming ...

"Despite the fact that multiple new procedures have come to light, nothing has the same excellent outcomes as HoLEP," says Amy E. Krambeck, MD. In this video, Amy E. Krambeck, MD, discusses the key ...

Panelists explore challenges in identification of patients with intermediate-risk disease and emphasize importance of risk stratification to improve outcomes with regard to NMIBC.